Meeting
2020 ASCO Virtual Scientific Program
Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.
Authors
Jeffrey E. Lancet
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Jeffrey E. Lancet , Geoffrey L. Uy , Laura F. Newell , Tara L. Lin , Ellen K. Ritchie , Robert K. Stuart , Stephen Anthony Strickland , Donna Hogge , Scott R. Solomon , Dale Bixby , Jonathan E. Kolitz , Gary J. Schiller , Matthew Joseph Wieduwilt , Daniel H. Ryan , Stefan Faderl , Yu-Lin Chang , Jorge Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01696084
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7510)
DOI
10.1200/JCO.2020.38.15_suppl.7510
Abstract #
7510
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.
First Author: Tara L. Lin
Poster
2023 ASCO Annual Meeting
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
First Author: Ellen K. Ritchie
Poster
2019 ASCO Annual Meeting
Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).
First Author: Ellen K. Ritchie
Poster
2017 ASCO Annual Meeting
Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.
First Author: Jeffrey E. Lancet